Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free SRZN Stock Alerts

Surrozen (SRZN) Competitors

Surrozen logo
$21.88 -0.93 (-4.08%)
Closing price 07/14/2026 04:00 PM Eastern
Extended Trading
$21.88 0.00 (0.00%)
As of 04:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SRZN vs. XNCR, ORIC, WVE, ALVO, and CGEM

Should you buy Surrozen stock or one of its competitors? MarketBeat compares Surrozen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Surrozen include Xencor (XNCR), Oric Pharmaceuticals (ORIC), WAVE Life Sciences (WVE), Alvotech (ALVO), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry.

How does Surrozen compare to Xencor?

Surrozen (NASDAQ:SRZN) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Xencor has higher revenue and earnings than Surrozen. Xencor is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surrozen$3.48M73.00-$242.03M-$37.59N/A
Xencor$125.58M8.83-$91.92M-$2.29N/A

66.6% of Surrozen shares are owned by institutional investors. 31.7% of Surrozen shares are owned by insiders. Comparatively, 5.1% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Xencor had 4 more articles in the media than Surrozen. MarketBeat recorded 6 mentions for Xencor and 2 mentions for Surrozen. Xencor's average media sentiment score of 0.66 beat Surrozen's score of 0.44 indicating that Xencor is being referred to more favorably in the news media.

Company Overall Sentiment
Surrozen Neutral
Xencor Positive

Surrozen presently has a consensus target price of $42.00, suggesting a potential upside of 91.96%. Xencor has a consensus target price of $24.25, suggesting a potential upside of 62.21%. Given Surrozen's higher possible upside, equities research analysts plainly believe Surrozen is more favorable than Xencor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surrozen
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.50
Xencor
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50

Surrozen has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Xencor has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Xencor has a net margin of -177.10% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Xencor's return on equity.

Company Net Margins Return on Equity Return on Assets
Surrozen-4,810.50% N/A -154.08%
Xencor -177.10%-28.77%-20.52%

Summary

Xencor beats Surrozen on 9 of the 16 factors compared between the two stocks.

How does Surrozen compare to Oric Pharmaceuticals?

Surrozen (NASDAQ:SRZN) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Surrozen currently has a consensus price target of $42.00, suggesting a potential upside of 91.96%. Oric Pharmaceuticals has a consensus price target of $19.27, suggesting a potential upside of 82.68%. Given Surrozen's higher probable upside, analysts clearly believe Surrozen is more favorable than Oric Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surrozen
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.50
Oric Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.75

Oric Pharmaceuticals has lower revenue, but higher earnings than Surrozen. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surrozen$3.48M73.00-$242.03M-$37.59N/A
Oric PharmaceuticalsN/AN/A-$129.47M-$1.44N/A

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Surrozen. MarketBeat recorded 5 mentions for Oric Pharmaceuticals and 2 mentions for Surrozen. Oric Pharmaceuticals' average media sentiment score of 1.77 beat Surrozen's score of 0.44 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Surrozen Neutral
Oric Pharmaceuticals Very Positive

Surrozen has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

66.6% of Surrozen shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Oric Pharmaceuticals has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Surrozen-4,810.50% N/A -154.08%
Oric Pharmaceuticals N/A -35.33%-33.31%

Summary

Oric Pharmaceuticals beats Surrozen on 10 of the 16 factors compared between the two stocks.

How does Surrozen compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

WAVE Life Sciences has a beta of -1.29, suggesting that its stock price is 229% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

WAVE Life Sciences currently has a consensus price target of $26.41, indicating a potential upside of 330.86%. Surrozen has a consensus price target of $42.00, indicating a potential upside of 91.96%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe WAVE Life Sciences is more favorable than Surrozen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WAVE Life Sciences
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.87
Surrozen
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.50

In the previous week, WAVE Life Sciences had 2 more articles in the media than Surrozen. MarketBeat recorded 4 mentions for WAVE Life Sciences and 2 mentions for Surrozen. WAVE Life Sciences' average media sentiment score of 1.07 beat Surrozen's score of 0.44 indicating that WAVE Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
WAVE Life Sciences Positive
Surrozen Neutral

WAVE Life Sciences has higher revenue and earnings than Surrozen. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WAVE Life Sciences$42.73M27.60-$204.38M-$1.06N/A
Surrozen$3.48M73.00-$242.03M-$37.59N/A

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by insiders. Comparatively, 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

WAVE Life Sciences has a net margin of -255.70% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat WAVE Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
WAVE Life Sciences-255.70% -56.76% -42.80%
Surrozen -4,810.50%N/A -154.08%

Summary

WAVE Life Sciences beats Surrozen on 11 of the 17 factors compared between the two stocks.

How does Surrozen compare to Alvotech?

Surrozen (NASDAQ:SRZN) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Surrozen has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Alvotech has higher revenue and earnings than Surrozen. Alvotech is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surrozen$3.48M73.00-$242.03M-$37.59N/A
Alvotech$588.90M1.69$27.92M-$0.25N/A

Surrozen currently has a consensus price target of $42.00, indicating a potential upside of 91.96%. Alvotech has a consensus price target of $7.60, indicating a potential upside of 130.30%. Given Alvotech's higher possible upside, analysts clearly believe Alvotech is more favorable than Surrozen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surrozen
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.50
Alvotech
2 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

66.6% of Surrozen shares are owned by institutional investors. 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alvotech has a net margin of -14.36% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Alvotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Surrozen-4,810.50% N/A -154.08%
Alvotech -14.36%-11.92%-7.59%

In the previous week, Surrozen and Surrozen both had 2 articles in the media. Alvotech's average media sentiment score of 1.14 beat Surrozen's score of 0.44 indicating that Alvotech is being referred to more favorably in the news media.

Company Overall Sentiment
Surrozen Neutral
Alvotech Positive

Summary

Surrozen beats Alvotech on 9 of the 16 factors compared between the two stocks.

How does Surrozen compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Cullinan Therapeutics has higher earnings, but lower revenue than Surrozen. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan TherapeuticsN/AN/A-$219.88M-$3.36N/A
Surrozen$3.48M73.00-$242.03M-$37.59N/A

Cullinan Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Cullinan Therapeutics currently has a consensus target price of $32.00, suggesting a potential upside of 80.08%. Surrozen has a consensus target price of $42.00, suggesting a potential upside of 91.96%. Given Surrozen's higher probable upside, analysts clearly believe Surrozen is more favorable than Cullinan Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cullinan Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Surrozen
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.50

Cullinan Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Cullinan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cullinan TherapeuticsN/A -51.45% -47.64%
Surrozen -4,810.50%N/A -154.08%

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Surrozen. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 2 mentions for Surrozen. Cullinan Therapeutics' average media sentiment score of 0.87 beat Surrozen's score of 0.44 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cullinan Therapeutics Positive
Surrozen Neutral

Summary

Cullinan Therapeutics beats Surrozen on 9 of the 16 factors compared between the two stocks.

Get Surrozen News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRZN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRZN vs. The Competition

Export
MetricSurrozenMED IndustryMedical SectorNASDAQ Exchange
Market Cap$264.83M$3.02B$6.86B$12.44B
Dividend YieldN/A2.08%2.68%8.42%
P/E Ratio-0.5818.7727.0124.38
Price / Sales73.00344.35521.3391.92
Price / CashN/A56.8348.5959.36
Price / Book-1.144.2010.956.33
Net Income-$242.03M$65.13M$3.59B$331.02M
7 Day Performance-4.37%-2.63%-1.45%-0.33%
1 Month Performance-5.45%2.14%2.78%-1.29%
1 Year Performance160.63%23.26%28.53%21.30%

Surrozen Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRZN
Surrozen
2.8835 of 5 stars		$21.88
-4.1%		$42.00
+92.0%		+154.1%$264.83M$3.48MN/A80
XNCR
Xencor
2.2305 of 5 stars		$15.73
-2.3%		$24.50
+55.8%		+68.9%$1.17B$125.58MN/A280
ORIC
Oric Pharmaceuticals
0.1508 of 5 stars		$11.10
+2.5%		$18.92
+70.5%		-2.8%$1.15BN/AN/A80
WVE
WAVE Life Sciences
3.0301 of 5 stars		$5.92
+1.8%		$26.41
+346.5%		-21.8%$1.14B$42.73MN/A240
ALVO
Alvotech
4.2573 of 5 stars		$3.67
-0.7%		$7.60
+107.4%		-62.9%$1.11B$588.90MN/A1,460

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SRZN) was last updated on 7/15/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel